Physician profile
Saad Ullah
NPI 1871978312
$6,101.96
in general payments reported to CMS, 2019-2025
29 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $90.67 · 2021: $43.85 · 2022: $488 · 2023: $2,032 · 2024: $1,782 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,133 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,133.30 |
| Education | $245.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,618.88 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,312.62 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $470.58 | 2022-2025 | Dupixent |
| Genzyme Corporation | $269.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.80 | 2023-2025 | Glassia |
| United Therapeutics Corporation | $257.89 | 2022-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $222.76 | 2023-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $221.75 | 2023-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $219.97 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.71 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $190.66 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $151.98 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $132.85 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Amgen INC. | $124.39 | 2022-2025 | Tezspire, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $70.88 | 2021-2024 | Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.72 | 2024-2025 | |
| Philips North America LLC | $48.36 | 2022-2024 | (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $46.59 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $33.99 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $32.84 | 2025 | Opsumit, Uptravi |
| Viatris Specialty LLC | $28.35 | 2025 | Yupelri |
| Inogen, INC. | $26.81 | 2022-2025 | |
| Pharming Healthcare, INC. | $19.70 | 2023 | Ruconest |
| Pulmonx Corporation | $17.50 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Inspire Medical Systems, INC. | $17.42 | 2025 | Inspire |
| Electromed, INC. | $16.26 | 2025 | Smartvest |
| Baxter Healthcare | $14.22 | 2025 | Hillrom - Monarch Airway Clearance System |
| Ani Pharmaceuticals, INC. | $14.07 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $13.22 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Ullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.